Table 2 Overall and subgroup meta-analysis of the association between SNHG20 expression and OS
From: Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis
Subgroup | Studies/N | Patient/N | Pooled HR (95% CI) | P value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
I2 | P value | Model | |||||
Overall | 15 | 1187 | 2.47 (2.05, 2.98) | 0.000 | 0.00% | 0.718 | Fixed-effect |
Cancer type | |||||||
Digestive system cancer | 5 | 483 | 2.91 (2.16, 3.92) | 0.000 | 0.00% | 0.726 | Fixed-effect |
Osteosarcoma | 2 | 172 | 1.95 (1.23, 3.09) | 0.005 | 0.00% | 0.973 | Fixed-effect |
Respiratory system cancer | 1 | 42 | 3.78 (1.18, 12.09) | 0.025 | – | – | – |
Reproductive system cancer | 2 | 153 | 2.16 (0.95, 4.87) | 0.065 | 0.00% | 0.390 | Fixed-effect |
Head and neck cancer | 3 | 151 | 1.97 (1.36, 2.85) | 0.000 | 0.00% | 0.722 | Fixed-effect |
Glioma | 2 | 186 | 3.27 (1.84, 5.82) | 0.000 | 50.00% | 0.157 | Fixed-effect |
Sample size | |||||||
>100 | 4 | 499 | 2.86 (2.09, 3.92) | 0.000 | 39.10% | 0.177 | Fixed-effect |
80–100 | 3 | 269 | 2.64 (1.81, 3.87) | 0.000 | 0.00% | 0.605 | Fixed-effect |
<80 | 8 | 419 | 2.09 (1.56, 2.81) | 0.000 | 0.00% | 0.929 | Fixed-effect |
Extracted method | |||||||
Direct | 5 | 539 | 2.55 (1.98, 3.29) | 0.000 | 36.70% | 0.176 | Fixed-effect |
Indirect | 10 | 648 | 2.38 (1.80, 3.14) | 0.000 | 0.00% | 0.903 | Fixed-effect |